<DOC>
	<DOCNO>NCT00494026</DOCNO>
	<brief_summary>This multicenter , phase II , open-label trial evaluate efficacy pemetrexed + carboplatin combine thoracic radiotherapy patient Limited Stage small cell lung cancer</brief_summary>
	<brief_title>Chemotherapy Radiotherapy Treat Patients With Limited Stage Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description>Two 21-day cycle pemetrexed ( 500 milligram per square meter [ mg/m2 ] intravenous [ IV ] infusion ) carboplatin ( target area curve [ AUC ] 5 IV infusion ) follow two 21-day cycle pemetrexed ( 500 mg/m2 IV infusion ) carboplatin ( target AUC 5 IV infusion ) concurrent radiotherapy ( 2 Gray [ Gy ] per fraction , 5 fraction per week , dose 50 Gy administer ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic and/or cytologic diagnosis Limited Stage small cell lung cancer Measurable disease Good performance status Adequate bone marrow reserve , hepatic , pulmonary renal function Serious concomitant systemic disorder Prior chemotherapy cancer and/or prior thoracic radiotherapy Pregnancy/breastfeeding Significant weight loss previous 6 week study entry Inability unwillingness take vitamin supplementation corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>